Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RARE Stock Forecast 2026-2027
$22.49
Current Price
$2.17B
Market Cap
Buy 20
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RARE Price Targets
+469.1%
To High Target of $128.00
+160.1%
To Median Target of $58.50
+2.3%
To Low Target of $23.00
RARE Price Momentum
-0.1%
1 Week Change
-31.5%
1 Month Change
-43.8%
1 Year Change
-2.2%
Year-to-Date Change
-51.6%
From 52W High of $46.50
+22.2%
From 52W Low of $18.41
📊 TOP ANALYST CALLS
Did RARE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ultragenyx is one of their latest high-conviction picks.
Latest RARE Stock Price Targets & Analyst Predictions
Based on our analysis of 36 Wall Street analysts, RARE has a bullish consensus with a median price target of $58.50 (ranging from $23.00 to $128.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $22.49, the median forecast implies a 160.1% upside. This outlook is supported by 20 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Whitney Ijem at Canaccord Genuity, projecting a 469.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RARE Analyst Ratings
20
Buy
1
Hold
0
Sell
RARE Price Target Range
Low
$23.00
Average
$58.50
High
$128.00
Current: $22.49
Latest RARE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RARE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 5, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $60.00 |
| Jan 5, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $52.00 |
| Jan 2, 2026 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $58.00 |
| Dec 30, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $45.00 |
| Dec 30, 2025 | Jefferies | Maury Raycroft | Buy | Maintains | $63.00 |
| Dec 30, 2025 | Leerink Partners | Joseph Schwartz | Outperform | Maintains | $70.00 |
| Dec 30, 2025 | Baird | Joel Beatty | Outperform | Maintains | $47.00 |
| Nov 24, 2025 | Barclays | Gena Wang | Overweight | Maintains | $50.00 |
| Nov 5, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $90.00 |
| Nov 5, 2025 | TD Cowen | Yaron Werber | Buy | Maintains | $75.00 |
| Sep 9, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $80.00 |
| Sep 5, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $105.00 |
| Aug 8, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $128.00 |
| Aug 6, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $105.00 |
| Jul 28, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Assumes | $80.00 |
| Jul 14, 2025 | Wedbush | Laura Chico | Neutral | Maintains | $34.00 |
| Jul 14, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $55.00 |
| Jul 10, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $65.00 |
| Jun 20, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $64.00 |
| May 28, 2025 | William Blair | Sami Corwin | Outperform | Initiates | $65.00 |
Ultragenyx Pharmaceutical Inc. (RARE) Competitors
The following stocks are similar to Ultragenyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ultragenyx Pharmaceutical Inc. (RARE) Financial Data
Ultragenyx Pharmaceutical Inc. has a market capitalization of $2.17B with a P/E ratio of -3.6x. The company generates $630.60M in trailing twelve-month revenue with a -91.9% profit margin.
Revenue growth is +14.7% quarter-over-quarter, while maintaining an operating margin of -106.9% and return on equity of -313.4%.
Valuation Metrics
Market Cap
$2.17B
Enterprise Value
$2.61B
P/E Ratio
-3.6x
PEG Ratio
-0.1x
Price/Sales
3.4x
Growth & Margins
Revenue Growth (YoY)
+14.7%
Gross Margin
+82.5%
Operating Margin
-106.9%
Net Margin
-91.9%
EPS Growth
+14.7%
Financial Health
Cash/Price Ratio
+19.6%
Current Ratio
1.9x
Debt/Equity
5,341.4x
ROE
-313.4%
ROA
-24.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ultragenyx Pharmaceutical Inc. (RARE) Business Model
About Ultragenyx Pharmaceutical Inc.
What They Do
Develops treatments for rare genetic diseases.
Business Model
Ultragenyx Pharmaceutical Inc. generates revenue by developing and commercializing novel biopharmaceutical products aimed at treating rare and ultra-rare genetic diseases. The company engages in various stages of product development, including clinical trials, and emphasizes collaborations with academic institutions and other pharmaceutical companies to enhance its innovative treatment approaches.
Additional Information
Founded in 2010 and headquartered in Novato, California, Ultragenyx is focused on niche markets within the biopharmaceutical industry, particularly in gene therapy and advanced biologic therapies, which are often overlooked due to smaller patient populations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,294
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.ultragenyx.comUltragenyx Pharmaceutical Inc. (RARE) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Affected investors can contact Danielle Peyton for more information.
Why It Matters
Ultragenyx faces potential legal claims, which may impact its stock price and investor confidence, prompting scrutiny of its financial health and future performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for potential federal securities law violations, notifying investors of the inquiry as of January 14, 2026.
Why It Matters
An investigation into Ultragenyx for potential federal securities law violations could lead to legal repercussions, affecting stock price and investor confidence.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation into Ultragenyx may indicate potential legal issues, which could impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ultragenyx Pharmaceutical Inc. (RARE) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting key developments and strategies for investors.
Why It Matters
Ultragenyx's presentation at a major healthcare conference highlights its strategic direction and potential developments, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
6 days ago
Quick Summary
Preliminary 2025 revenue is projected at $672M-$674M, surpassing guidance. Cash and investments are about $735M. Potential 2026 catalysts include two approvals and Phase 3 data for GTX-102.
Why It Matters
Strong revenue projections and significant cash reserves indicate financial stability, while upcoming drug approvals could drive growth and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A Wells Fargo analyst lowered the price target for Ultragenyx, despite it suggesting upside from the closing price. The company reported two Phase 3 studies for setrusumab did not meet primary endpoints.
Why It Matters
The price target cut reflects reduced confidence in Ultragenyx's growth potential after failed trials, impacting investor sentiment despite the implied upside.
Source: The Motley Fool
Market Sentiment:
Negative
Frequently Asked Questions About RARE Stock
What is Ultragenyx Pharmaceutical Inc.'s (RARE) stock forecast for 2026?
Based on our analysis of 36 Wall Street analysts, Ultragenyx Pharmaceutical Inc. (RARE) has a median price target of $58.50. The highest price target is $128.00 and the lowest is $23.00.
Is RARE stock a good investment in 2026?
According to current analyst ratings, RARE has 20 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RARE stock?
Wall Street analysts predict RARE stock could reach $58.50 in the next 12 months. This represents a 160.1% increase from the current price of $22.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ultragenyx Pharmaceutical Inc.'s business model?
Ultragenyx Pharmaceutical Inc. generates revenue by developing and commercializing novel biopharmaceutical products aimed at treating rare and ultra-rare genetic diseases. The company engages in various stages of product development, including clinical trials, and emphasizes collaborations with academic institutions and other pharmaceutical companies to enhance its innovative treatment approaches.
What is the highest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The highest price target for RARE is $128.00 from Whitney Ijem at Canaccord Genuity, which represents a 469.1% increase from the current price of $22.49.
What is the lowest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The lowest price target for RARE is $23.00 from at , which represents a 2.3% increase from the current price of $22.49.
What is the overall RARE consensus from analysts for Ultragenyx Pharmaceutical Inc.?
The overall analyst consensus for RARE is bullish. Out of 36 Wall Street analysts, 20 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $58.50.
How accurate are RARE stock price projections?
Stock price projections, including those for Ultragenyx Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 5:27 PM UTC